Adult stem cells are promising cellular vehicles for therapy of malignant gliomas as they have the ability to migrate into these tumors and even track infiltrating tumor cells. However, their clinical use is limited by a low passaging capacity that impedes large-scale production. In the present study, a bone marrow-derived, highly proliferative subpopulation of mesenchymal stem cells (MSCs)-here termed bone marrow-derived tumor-infiltrating cells (BM-TICs)-was genetically modified for the treatment of malignant glioma. Upon injection into the tumor or the vicinity of the tumor, BM-TICs infiltrated solid parts as well as the border of rat 9L glioma. After intra-tumoral injection, BM-TICs expressing the thymidine kinase of herpes simplex virus (HSV-tk) and enhanced green fluorescent protein (BM-TIC-tk-GFP) were detected by non-invasive positron emission tomography (PET) using the tracer 9-[4-[ A therapeutic effect was demonstrated in vitro and in vivo by BM-TICs expressing HSV-tk through bystander-mediated glioma cell killing. Therapeutic efficacy was monitored by PET as well as by magnetic resonance imaging (MRI) and strongly correlated with histological analysis. In conclusion, BM-TICs expressing a suicide gene were highly effective in the treatment of malignant glioma in a rat model and therefore hold great potential for the therapy of malignant brain tumors in humans.
IntroductIon
Malignant gliomas still have a dismal prognosis despite advances in neurosurgery and adjuvant radio-and chemotherapy. One major reason is their infiltrative growth pattern, with single tumor cells migrating distantly from the solid tumor mass and infiltrating normal brain tissue, where they can cause recurrent tumors. Novel therapies should aim to target these infiltrating cells, too.
One very promising therapeutic approach is the intra-tumoral delivery of adult stem cells that express therapeutic genes. Stem cells are suitable cellular vehicles for glioma therapy as they have the ability to migrate to a pathologic focus. Several groups of researchers have shown that neural and mesenchymal stem cells (NSCs and MSCs) migrate specifically to and into malignant gliomas and even track infiltrating tumor cells.
1-3 However, there are two important limitations in terms of large-scale production of these cells for clinical application. NSCs can be isolated only from fetal or adult brain or generated from embryonic stem cells. In addition, they have a very limited passaging capacity in vitro. MSCs, although easy accessible from the bone marrow, also have a low passaging capacity, with a maximum of up to 5-50 population doublings (PDs) in vitro. 4, 5 So far, these stem cells can be expanded efficiently only after introduction of a growthpromoting gene. Examples are MSCs that are transfected with the human telomerase reverse transcriptase gene 4 or the murine NSC line C17.2, 6 genetically modified to express c-myc. An attractive option for clinical use is a highly proliferative subpopulation of bone marrow-derived MSCs called bone marrow-derived multipotent adult progenitor cells (MAPCs), which can be expanded for more than 100 PDs without exogenous immortalization. MAPCs are pluripotent and differentiate into most somatic tissues in vivo when injected into an early blastocyst. 7 In our study, we derived bone marrow cells according to the original protocol published by Jiang et al. 7 As described for MAPCs, the isolated cells were negative for CD44, CD90, and major histocompatibility complex (MHC) class I antigens, 7 whereas all three markers are found on MSCs. 8, 9 Our study focused on the tumor-infiltrating ability of this MAPClike cell population rather than on their capacity to differentiate into different lineages. Therefore, we here name these MAPClike cells bone marrow-derived tumor-infiltrating cells (BMTICs). BM-TICs were compared with various cell lines that can be expanded to high cell numbers for their migratory behavior in malignant glioma in vivo. We demonstrated that BM-TICs have a migratory capacity similar to other stem cell lines, whereas hematopoietic cell lines and fibroblast control cells were unable to migrate specifically. BM-TICs were transduced with a retroviral vector expressing the thymidine kinase of herpes simplex virus (HSV-tk) and the green fluorescent protein (BM-TIC-tk-GFP) and traced by non-invasive positron emission tomography (PET). A bystander-mediated therapeutic effect of BM-TIC-tk-GFP for glioma cells was demonstrated in vitro and in vivo.
results

Phenotypic characterization of rat BM-tIcs and Mscs
BM-TICs were obtained from the bone marrow of adult Fischer rats according to the protocol for isolation and expansion of MAPCs. 7 The expression of different cell-surface markers was analyzed by flow cytometry. BM-TICs were negative for CD31, CD44, CD45, CD90, CD105, CD106, and MHC class I, whereas MSCs expressed CD44, CD90, and MHC class I, as described in the literature (Table 1) . [7] [8] [9] BM-TICs were thus phenotypically distinct from the classical MSC population.
Migratory capacity of BM-tIcs and hematopoietic cell lines in 9l glioma in vivo
Cell lines with a high passaging capacity, which are suitable for genetic modification and large-scale production, were tested for migration in a rat glioma model. In this study, BM-TICs were used at PDs of . No major influence of the passage number on the migratory behavior described below was observed.
We investigated whether BM-TIC, K562, Jurkat, or Raji cell lines infiltrate established malignant glioma. The NSC line C17.2, for which migration has been shown in a previous study, 1 was used as positive control, and 3T3 as negative control. To rule out the interference of an immune (Supplementary Figure S1 ) response against allogeneic cell lines with their migration ability, syngeneic Fischer rat fibroblasts Rat-1 were used as a second negative control. Glioma cells (9L glioma cell line) transduced with the red fluorescence gene DsRed (9LDsRed) were implanted into the striatum of Fischer rats, and 5 days thereafter enhanced GFP (eGFP)-transduced cell lines were injected into established tumors or in the vicinity of tumors. At 3 and 7 days after implantation of the distinct cell lines, rats were killed and brain sections were analyzed by fluorescence microscopy. Within 3 days after injection, BM-TICs had migrated from the injection site to the tumor border (Figure 1a) as well as into the solid tumor areas (Figure 1b) . At day 7, BM-TICs had infiltrated the majority of the solid tumor mass (Figure 1c ) and were also found at the tumor border, even tracking tumor cells infiltrating the normal tissue (Figure 1d) . Importantly, BM-TICs did not migrate into normal brain tissue without having been triggered by a tumor cell. The NSC line C17.2 showed a similar migratory behavior (Figure 1e) . In contrast, 3T3 cells remained at the injection site and were well demarcated from the tumor tissue (Figure 1f) . 3T3 cells did not migrate toward the border of the tumor or infiltrating tumor cells. The cell line K562 was detected in the brain adjacent to the tumor mass surrounding the tumor (Figure 1g) . The same was observed for Jurkat and Raji cells (data not shown). Cells of these lines were not found in the tumor mass. However, individual cells were detected in normal 
Gap junction formation between BM-tIcs and 9l cells
The formation of gap junctions between therapeutic cells and tumor cells is critical in a suicide gene therapy approach, as gap junctions are responsible for the bystander effect. Gap junction communication between cells can be measured by dye-transfer experiments and flow cytometry. 10 In these experiments, one cell population contains a non-membrane-permeable dye that is taken up by another cell population upon incubation. Here, 9L cells were labeled with the membrane dye 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) and incubated together with BM-TICs containing the non-membrane-permeable dye calcein-AM. As shown in Figure 2a , 9L/DiI and BM-TIC/ calcein-AM cells form two distinct populations of either red-or green-fluorescent cells immediately after mixing. After 3 hours of incubation, however, 9L/DiI cells have taken up green-fluorescent calcein-AM and appear as a population of double-positive redand green-fluorescent cells (Figure 2b) , whereas BM-TICs have lost intensity of green fluorescence owing to transfer of calcein-AM and taken up more DiI. DiI cannot be transferred from one cell to another as it is a membrane-bound protein. However, DiI can be set free from apoptotic cells (during the incubation period, by trypsinization, before or during flow cytometry) and thereafter can bind to the membrane of living cells (9L cells and BM-TICs), which might explain the shift in both populations. In contrast, cytoplasmatic or free calcein-AM can be taken up by a living cell only via gap junctions. Therefore, the shift of 9L/DiI in the direction of calcein-AM can be explained only by gap-junctional communication.
In vitro bystander killing of 9l glioma cells by BM-tIcs expressing HsV-tk BM-TICs were transduced with a retroviral vector expressing the HSV-tk suicide gene (BM-TIC-tk; see Materials and Methods). The bystander killing effect of BM-TIC-tk on 9L-DsRed glioma cells was examined by co-culture experiments. After addition of ganciclovir (GC) to the medium, BM-TIC-tk exerted a strong and dose-dependent bystander effect on glioma cells (Figure 3) . Killing of 90% of glioma cells was achieved in cultures containing 50% or even only 10% BM-TIC-tk. Killing was statistically significant with GC concentrations ranging from 10 −3 to 10 3 µmol/l for 50% BM-TIC-tk and from 10 −2 to 10 3 µmol/l for 10% BM-TIC-tk. In contrast, 9LDsRed cells mixed with native BM-TICs were resistant to GC up to high concentrations (Figure 3) . These experiments show that BM-TIC-tk can be used to deliver toxic molecules, such as phosphorylated GC, to glioma cells.
In vivo bystander killing of 9l glioma cells by BM-tIc-tk-GFP
To analyze the therapeutic effect of BM-TICs in vivo, BM-TICs transduced with HSV-tk and GFP (BM-TIC-tk-GFP) were injected into 9L tumors 5 days after tumor implantation. As a control, non-migrating Rat-1 transduced with HSV-tk and GFP (Rat-1-tk-GFP) were implanted. From day 4 after cell injection, one group of BM-TIC-implanted rats (n = 9), one group of Rat-1-implanted rats (n = 8), and one control group implanted with 9L only (n = 8) received daily intraperitoneal injections of 30 mg per kg GC for 10 days. Two control groups of BM-TIC-tk-GFP-(n = 8) or Rat-1-tk-GFP-implanted rats (n = 8) were not treated with GC. Kaplan-Meier survival analysis showed more than 60% long-term survivors in the BM-TIC-tk-GFP plus GC-treated group surviving for 110 days (Figure 4a ). Two out of nine animals died at day 28, and one died at day 54 after tumor implantation. All animals in the control groups died within the observation period. Thus, treated animals showed a prolonged survival compared with both Therapy of Glioma with Progenitor Cells control groups that was statistically highly significant (P < 0.001). In contrast, Rat-1-tk-GFP and GC-treated animals showed a significantly reduced survival compared with BM-TIC-tk-GFP and GC-treated animals (P < 0.01), but also a significantly prolonged survival compared with control groups (P < 0.05).
Tumor cells were not detected on serial histological sections in the brains of BM-TIC-tk-GFP plus GC-treated long-term survivors. A cavity and scar tissue resulting from the initial tumor mass, which had been successfully treated, was observed in long-term survivors and was infiltrated by CD45-positive inflammatory cells (Figure 4b and c) .
detection of HsV-1-tk-GFP-transduced BM-tIcs and therapeutic follow-up by Pet and MrI
For clinical application of therapeutic cells, it is essential to be able to locate these cells using non-invasive methods. For this purpose, BM-TIC-tk-GFP cells were injected into 9LDsRed tumors, and (Figure 5a and b) , and fluorescence microscopy of ]FHBG uptake in BM-TIC-tk-GFP-injected animals (0.113 ± 0.025% of the injected dose/g; n = 3) was significantly higher (P < 0.05) than in the control group (0.053 ± 0.006% of injected dose/g; n = 3). Shown are the mean values of each group. P refers to levels of statistical significance between the BM-TIC-tk-GFP and 9LDsRed-only groups. Student's t-test for non-discrete grade values. *P < 0.05. histological sections confirmed eGFP-positive cells at the border and in solid tumor parts (Figure 5e) . The relative expression level of HSV-tk was 0.113 ± 0.025% of the injected dose/g tissue (Figure 5f ). In contrast, animals that had received glioma cells only (control group) had a significantly lower [ For treatment with GC, the animals were divided into three groups as described above for the survival study. On day 6 and day 7 or 8 after tumor implantation and before GC treatment, tumors were detected by MRI and [ 11 C]MET PET scans, respectively (Figure 6a-f) . In animals without GC treatment, implanted BM-TIC-tk-GFP cells were detected by [ 18 F]FHBG PET scans 7 days after implantation (Figure 6h) . In contrast, animals with 3 days of GC treatment had an uptake similar to control animals that received 9LDsRed cells and GC (Figure 6g and i) , indicating loss of HSV-tk activity as a result of the treatment. Five days after initiation of GC treatment, the tumor size of treated animals was reduced compared with both control groups, as shown on MRI and [ 11 C]MET PET scans (Figure 6j-o) . As determined by semiquantitative estimations based on the size of the hyperintense lesion in gadopentetic acid-enhanced (Gd-DTPA) three-dimensional MRI, the tumor size in the treated animals was 20-40% that of both controls on day 13. Three to five days after termination of GC application, animals with a good response to treatment exhibited a low contrast-enhancing lesion in MRI (Figure  6p) and only a very weak signal in [ 11 C]MET PET (Figure 6q) . The hyperintense lesion for individual animals increased from day 7-8 to day 13 by a factor of 1.7 ± 0.3 for the treated animals and by a factor of 6.1 ± 0.5 for both control groups. The lesion size in the treated animals did not change significantly between day 13 (during GC treatment) and day 21 (after GC treatment; change by a factor of 0.95 ± 0.1). Compared with day 13, lesion appearance in the final MRIs was very heterogeneous, indicating the possible presence of cystic and necrotic compartments. By histology, only residual tumor cells were detected, surrounded and intermingled with CD45-positive inflammatory cells (Figure 7a,  d and e) . The latter consisted predominantly of CD8 + T cells. In addition, CD4 + T cells, ED1 + macrophages, and CD161 + natural killer cells were seen (Figure 7f-i) . In both control groups, animals became terminally ill during the treatment and were killed. Histology revealed large tumor masses (Figure 7b and c) that contained less prominent leukocytic infiltrations compared with the treated group (Figure 7j-o) .
These data demonstrate that PET imaging is a suitable method to detect therapeutic cells in vivo. Furthermore, the strong correlation with histological data confirmed that PET/MRI is a useful method to monitor the therapeutic response non-invasively in individual animals.
dIscussIon
This study demonstrates that a subpopulation of bone marrowderived MSCs can be used as tumor-infiltrating therapeutic cells against malignant glioma. These BM-TICs exhibited a migratory behavior similar to that of NSCs and MSCs.
1-3 They migrated from the injection site to the border of the tumor and also infiltrated solid tumor parts. Importantly, they even appeared to track infiltrating glioma cells, as already described for NSCs by Aboody et al. 1 This feature is of great significance because, at present, infiltrating glioma cells cannot be targeted successfully and are therefore responsible for recurrent tumors and the poor prognosis of glioblastoma patients.
However, the use of NSCs and MSCs in clinical application is hampered by their low passaging capacity, which is in the range 5-50 PDs. 4, 5 A higher passaging capacity can be obtained only by gene modification of stem cells with oncogenes or other genes promoting cell proliferation. 4, 6 But these modifications are associated with a higher risk of tumorigenicity. In this regard, it has been demonstrated that long-term cultures of telomerase-transduced human MSCs may accumulate spontaneous genetic changes leading to tumorigenicity in immunodeficient mice. 11 A second obstacle for clinical application is that NSCs can be isolated only from fetal or adult brain or from embryonic stem cells. In contrast, the BM-TICs used in this study have all the requirements for an applicable glioma therapy: they can be isolated easily from bone marrow, they can be passaged for more than 100 PDs, 7 and they show a specific migration in malignant glioma.
Phenotypically, BM-TICs were found to resemble the MAPCs described by Verfaillie's group and to differ substantially from classical MSC: rat BM-TICs stained negative for CD44, CD90, and MHC class I, as first reported by Jiang et al. for MAPCs, 7 whereas rat MSCs express these markers. CD44, CD90, and MHC class I are also expressed on human MSCs 8,9,12 but are absent or expressed at low levels (CD44) on human MAPCs. 13 Furthermore, we demonstrated that gene-modified BM-TICs can be used for glioma therapy in rats. Our cell culture experiments showed that BM-TIC-tk-GFP cells exert a strong bystander effect on 9L glioma cells upon GC treatment. In vivo, more than 60% of BM-TIC-tk-GFP plus GC-treated animals were long-term survivors. In contrast, animals treated with non-migrating, syngeneic fibroblasts Rat-1-tk-GFP plus GC survived significantly shorter, without long-term survival. The HSV-tk/GC system is considered to be highly effective for cancer therapy. [14] [15] [16] [17] The prodrug GC is phosphorylated by the enzyme HSV-tk into cytotoxic GC-P and is transported via gap junctions to neighboring cells, thus exerting a bystander effect on non-gene-modified cells. 18 The role of gap junctions in this process has been verified by co-culture experiments of connexin-expressing and connexindeficient cells. 19 We confirmed gap junction communication between BM-TICs and 9L cells by dye transfer of calcein-AM. Calcein-AM is non-fluorescent until it is taken up by cells and cleaved by cellular esterases. Processed calcein-AM is a green fluorescent dye that does not diffuse through the cellular membrane. However, intercellular transfer of calcein-AM can occur through cell-cell communication channels (gap junctions), which can be measured by flow cytometry. 10 This communication is the basis for the strong therapeutic bystander effect of the HSV-tk/GC system, which can compensate for low transduction efficiencies. Thus, the HSV-tk/GC system is widely used in strategies targeting various types of cancer cells by viral vectors. However, clinical trials for glioma using this system have failed. 20, 21 One major reason may be the delivery method of HSV-tk into glioma cells: viral vectors and fibroblasts used as packaging cells for viral vectors both mediate gene modification of cells only in the direct vicinity of the injection site and therefore fail to transduce infiltrating tumor cells or distant tumor areas. In this study, migrating BM-TICs modified with a therapeutic gene that exerts a bystander effect could partially overcome this problem.
An even greater therapeutic efficacy might be achieved if the infiltrating cells were modified to produce a viral vector that transfers the therapeutic gene(s) efficiently and selectively to the tumor cells. NSCs expressing HSV-tk have been shown to mediate a therapeutic bystander effect in vitro and in vivo similar to that observed in our study. 22, 23 However, the establishment of a stable packaging cell line for in vivo delivery of viral vectors based on NSCs would be hampered by the low expansion capacity of these cells. In this regard, our recently established stable packaging cell line based on BM-TICs producing retroviral vectors pseudotyped with glycoproteins of the lymphocytic choriomeningitis virus, a vector pseudotype that transduces glioma cells with a high specificity and efficacy, [24] [25] [26] [27] may be useful. In fact, upon injection into 9L rat glioma, packaging cells showed a similar intra-tumoral distribution to that reported here and mediated transduction of glioma cells in solid as well as infiltrating tumor parts. In addition to its therapeutic effect, HSV-tk has gained increasing attention as a marker for non-invasive imaging. The expression of the HSV-tk protein, which selectively incorporates certain radiolabeled nucleoside analogues into DNA, [29] [30] [31] can be non-invasively imaged in distinct regions of a transduced tissue. 29, [32] [33] [34] [35] [36] [37] Therefore, HSV-tk-based PET imaging has been used to evaluate the transduction efficiency of viral vector-mediated gene therapy applications in vivo. [38] [39] [40] In our study, this technique was applied to localize therapeutic cells in vivo. The visualization of therapeutic cells within a tumor is an important clinical issue as the intra-tumoral distribution of these cells is the prerequisite for an efficient therapeutic effect. Using the HSV-tk-specific tracer [ In addition, the therapeutic effect of BM-TIC-tk-GFP treatment was monitored successfully during and after termination of GC treatment by MRI and [ 11 C]MET PET imaging. In general, tumors of animals in the therapeutic group were reduced in size compared with those of control animals. Histopathology revealed only residual tumor cells in the treatment group and large tumor masses in both control groups, showing that imaging data were strongly correlated with histology. Furthermore, a strong immune reaction was evident at the initial tumor site of treated animals, predominantly consisting of CD8 + T cells with additional CD4 + T cells, ED1 + macrophages, and CD161 + natural killer cells, whereas control animals showed less prominent leukocytic infiltrates in large tumor masses. These data suggest that the therapeutic effect was in part mediated by the immune response. A similar immunologic bystander effect was observed in other gene therapy studies using viral vectors or viral vector packaging cell lines to deliver HSV-tk to tumor cells. 14, 43 In conclusion, in bone marrow-derived progenitor cells, all relevant features for the translation of a cell-based therapy into the clinic are combined. In addition to their migratory ability, they show a high passaging capacity, which allows genetic modification and large-scale production. Furthermore, they can be noninvasively imaged in vivo and they transmit a bystander-mediated and immune response-supported therapeutic effect through the HSV-tk/GC paradigm in experimental malignant glioma.
MaterIals and MetHods
Cell lines. The human embryonic kidney cell line 293T [American Type Culture Collection (ATCC) number CRL-11268], the murine fibroblast cell line NIH 3T3 (ATCC number CRL-1658), the 9L cell line, and the syngeneic Fischer rat fibroblast cell line Rat-1 were obtained from ATCC (Manassas, VA) and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% glutamine. The B-cell line Raji (ATCC number CRL-86), the T-cell line Jurkat (ATCC number TIB-152), and the myeloid cell line K562 (ATCC number CCL-243) were obtained from ATCC and maintained in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal calf serum and 1% glutamine. All cell lines were grown in a humidified atmosphere of 5% CO 2 .
Isolation and culture of rat MSCs. MSCs were isolated from rats and cultured as previously described.
44
BM-TIC isolation and culture. BM-TICs were prepared from bone marrow as previously described. Transduction of 9L cells with DsRed. 9L cells were transduced as described previously.
25 Double-dye transfer assay. To assess gap junction communication between 9L glioma cells and BM-TICs, 9L cells were stained with the membrane-binding red fluorescent dye DiI (Molecular Probes, Karlsruhe, Germany), whereas BM-TICs were stained with calcein-AM (Molecular Probes). Stainings with DiI (5 µl per ml cell suspension) and calcein-AM (0.75 µM) were performed according to the manufacturer's instructions. After staining, 9L cells and BM-TICs were washed three times with phosphate-buffered saline, mixed at a ratio of 1:1, and seeded at 5 × 10 5 cells/ well into 24-well plates. Cells were incubated for 3 hours at 37 °C. Calcein-AM transfer from BM-TICs to 9L cells was assessed using a flow cytometer (BD, Heidelberg, Germany).
Bystander-mediated killing of 9L cells in vitro.
Mixtures of 9LDsRed with BM-TIC-tk cells or 9LDsRed with BM-TICs were seeded into fibronectincoated 96-well plates in Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum. Mixtures contained either 10% or 50% BM-TIC-tk cells or BM-TICs, respectively. The total cell number per well was 1 × 10 4 cells. Cells were incubated for 4 hours; thereafter, medium was Therapy of Glioma with Progenitor Cells changed and 100 µl Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum containing increasing concentrations of GC was added. After a 3-day incubation period, medium was removed, and cells were washed three times with phosphate-buffered saline and subsequently lysed by adding 100 µl of radio-immunoprecipitation assay buffer [150 mmol/l NaCl, 50 mmol/l Tris, 1% (vol/vol) Triton X-100, pH 7.3]. Fluorescence intensity in the lysates, corresponding to the number of living 9LDsRed cells at the time of cell lysis, was determined using a Fluorostar Optima plate reader (BMG Labtechnologies, Offenburg, Germany).
Implantation of 9L and cell lines. Adult female Fisher 344 rats (Harlan Winkelmann, Borchen, Germany) were anesthetized by intraperitoneal injection of ketamine (50 mg per kg) and xylazine (2 mg per kg). Intracranial 9LDsRed or 9L tumors were established by injection of 8 × 10 4 9LDsRed cells or 6 × 10 4 9L cells (in 2 µl phosphate-buffered saline) into the right striatum, respectively, using a Hamilton syringe in a stereotactic apparatus (Stoelting, Wood Dale, IL). The coordinates used were 4 mm lateral to the bregma and 5 mm below the dural surface. Five days after tumor implantation, rats were anesthetized, and different cell lines were injected using the same stereotactic coordinates. In the migration experiment 10 5 cells and in the treatment experiments 6 × 10 5 cells of each cell line were implanted.
Analysis of migration of test cells within brain tumors.
Animals were killed and perfused with 4% paraformaldehyde. Brains were removed, suspended in 30% sucrose for 3 days, and snap-frozen in isopentane chilled with liquid nitrogen. Coronal cryostat sections (12 µm) were prepared and examined under a fluorescence microscope (Zeiss, Jena, Germany). All animal procedures were carried out in accordance with the regulations established by the German Committee for Animal Care and Use.
Treatment of rat gliomas. Fischer rats either bearing 9L tumors or bearing 9L tumors and having been implanted with BM-TIC-tk-GFP or Rat-1-tk-GFP were treated by daily intraperitoneal injections of 30 mg per kg GC for 10 days, starting at day 4 after BM-TIC-tk-GFP or Rat-1-tk-GFP implantation.
Histology and immunohistochemistry. Animals were killed and perfused as described above. Cryostat sections were stained with hematoxylin and eosin (H&E; Merck, Darmstadt, Germany). For immunohistochemistry, the primary mouse anti-rat antibodies directed against LCA (Becton Dickinson, Heidelberg, Germany), CD4 (Becton Dickinson), CD8 (Becton Dickinson), ED1 (Acris, Hiddenhausen, Germany), and CD161 (Becton Dickinson) were used. Immunohistochemistry was performed using the avidin-biotin-complex technique with appropriate biotinylated secondary antibodies (Vectastain Elite kit; Vector Laboratories, Burlingame, CA) and visualizing peroxidase reaction product using 3,3′-diaminobenzidine (Sigma, Munich, Germany) as chromogene and H 2 O 2 as co-substrate. PET. PET imaging was performed using a microPET (Concorde Microsystems, Knoxville, TN; 63 image planes; 2.0 mm full width at half maximum). Radiotracer was administered intravenously (caudal vein) into experimental animals at the following doses: no-carrier-added [ F]FHBG) after tracer application. Images were reconstructed using Fourier rebinning and two-dimensional filtered-back projection (microPET). For quantification of images, a reference standard sample of radiotracer was placed within the field of view of the PET scanner. Image registration and data evaluation based on a region-of-interest (ROI) analysis of PET images to determine maximal radioactivity concentrations within tumors were performed using VINCI (MPI Cologne, Cologne, Germany), a newly developed, fast graphical image analysis tool. 46 After background (contralateral hemisphere) subtraction, data were decay-corrected and divided by the total injected dose to represent percentage injected dose per gram.
Radiosynthesis of radiotracers [
Localization of tumor before and during gene therapy was performed by MRI and [
11 C]MET PET. The respective PET images were registered to the MRIs.
MRI. Animals were imaged after administration of approximately 1 ml/g body weight gadopentetic acid (500 mM, Magnevist; Schering, Berlin, Germany). Animals were anesthetized using 1% halothane in O 2 :N 2 O (35:65%). Temperature was maintained at 37 °C and monitored throughout the MRI measurements. All MRIs were acquired using a Bruker Biospin 4.7 T small-animal scanner (Ettlingen, Germany; horizontal bore, 30 cm) equipped with actively shielded gradients (200 mT/m). Purpose-built radio-frequency coils were used (12-cm Helmholtz coils for excitation and a 3-cm surface coil for detection). After two-dimensional localization scans, three-dimensional gradient-echo scans (FLASH) with T1 weighting were acquired. The acquisition parameters were spatial resolution = 121 × 121 × 242 µm 3 , field of view = 31 × 31 × 15.5 mm 3 , repetition time = 70 ms, echo time = 5 ms, flip angle = 60°. Images were processed using Paravision 3.2 (Bruker Biospin, Karlsruhe, Germany) and VINCI for registration with PET data. Lesion volumes were estimated based on the hyperintense region in three-dimensional T1-weighted images after gadopentetic acid administration using the National Institutes of Health program ImageJ.
Statistical analysis.
Survival was analyzed with a log-rank test based on the Kaplan-Meier test using SPSS software (SPSS GmbH, Munich, Germany). Differences between pairs of groups were determined using the Student's t-test. P < 0.05 was considered significant.
